Resources/
Phil Blog

Phil Blog

Press Release: PHIL Secures $60M Growth Capital from K2 HealthVentures to Accelerate AI Integration

Phil, a leading software-driven pharmaceutical commercialization platform, today announced a $60 million growth debt financing from K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm. The funding will accelerate the integration of artificial intelligence across Phil's platform and support continued customer expansion across a broad range of therapeutic areas.

BioPharma Dive: Bridging Data Gaps that Impact Retail and Specialty-Lite Success

Retail and specialty-lite brand teams are facing a paradox – they’re drowning in data yet struggling to gain actionable insight. While manufacturers collect vast amounts of information, most are still making critical business decisions based on incomplete data sets that fail to capture the full prescription journey.

Drug Channels: Harnessing the Power of Comprehensive Data to Drive GTN

Growing market access barriers are compelling retail and specialty-lite pharmaceutical manufacturers to seek new approaches to optimize revenue and enhance patient access. Traditional data sources and siloed solutions are no longer sufficient to address the challenges of formulary exclusions and rising patient out-of-pocket costs. Success in today's market requires comprehensive visibility across the patient journey to drive meaningful improvements in gross-to-net (GTN) performance.

Meet Bob Schumaker, Vice President of Operations at PHIL

As VP of Operations at PHIL, Bob Schumaker champions a collaborative approach that brings together healthcare stakeholders to improve patient care. Drawing from his extensive background, Bob has spent the last five years building and scaling PHIL's partnership operations with a laser focus on improving patients' lives. Can you tell us a little bit about what your role as VP of Operations entails

How Can Pharma Manufacturers Improve Patient Engagement in 2025?

Patient engagement is a critical factor for brand success. Not only does patient engagement benefit patients by addressing unmet needs more effectively, but it has also proven to be a powerful driver of financial value. A groundbreaking study revealed that an investment of $100,000 in patient engagement could increase net present value and expected net present value by more than 500-fold the investment – the equivalent of accelerating a pre-phase 2 product launch by 2.5 years

Create a Path to Commercial Success

Our expert team can build a tailored access program that drives your brand goals.